1.01
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Werewolf Therapeutics
From its filings with the US Securities and Exchange Commission
Werewolf Therapeutics is based in Waltham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HOWL. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $60.8m. At that date it held total assets of $69.4m and shareholders' equity of $24.8m.
We are also utilizing this PREDATOR platform know-how and expertise to develop conditionally activated immune cell engagers. Immune cell engagers, such as T cell engagers, are typically bispecific antibodies that redirect immune cells to cancer cells via engagement with tumor associated cell surface antigens, leading to immune cell mediated killing of the cancer cells. We have provided initial preclinical data for our proprietary INDUCER™ T cell engager molecules demonstrating that our PREDATOR masking technology silenced peripheral activity and prevented cytokine release.
In February 2026, we adopted a restructuring plan to extend our capital resources in connection with initiating a process to explore a full range of strategic alternatives to advance our promising platform and drug development pipeline to maximize stockholder value. We have engaged Piper Sandler & Co, or Piper Sandler, to serve as exclusive financial advisor to assist in the strategic review process. Measures contemplated during the strategic review process may include, among other options, a sale of our company, a business combination or merger, a sale of our assets, licensing or collaboration arrangements, or other strategic transactions. There can be no assurance that the strategic review process will result in any agreement or transaction that will enhance stockholder value, or any agreement or transaction at all.
Quoted from its 10-K, filed 27 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Apr 2021
- Employees
- 46
- Website
- werewolftx.com ↗
- Head office
- 303 WYMAN STREET, WALTHAM, MA, 02451
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Dr. Luke EvninIndependent Chairman of the Board, since 2017$147,479
- Dr. Daniel HicklinPresident, Chief Executive Officer, Director, since 2017$2.5m
- Mr. Timothy TrostChief Financial Officer, Treasurer$1.2m
- Dr. Chulani KarunatilakeChief Technology Officer$3.9m
- Mr. Steven BloomChief Business Officer
- Dr. Randi IsaacsChief Medical Officer$1.4m
- Dr. Briggs MorrisonDirector$104,479
- Dr. Michael AtkinsIndependent Director$279,695
- Dr. Meeta ChatterjeeIndependent Director$113,479
- Dr. Alon LazarusIndependent Director$121,979
- Mr. Michael ShermanIndependent Director$124,479
- Dr. Anil SinghalIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 48
- Social
- 74
- Governance
- 21
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Werewolf Therapeutics' PREDATOR platform enables conditionally activated molecules for cancer treatment.
- WTX-124 and WTX-330 are clinical-stage products targeting solid tumors and Non-Hodgkin Lymphoma.
- The company employs 46 full-time staff focused on immune system stimulation therapies.
Weaknesses
- The company has only 46 employees, which may limit research and development capacity.
- Werewolf Therapeutics' IPO occurred in April 2021, indicating a relatively new market presence.
- The firm's focus on a single platform may restrict diversification in therapeutic approaches.
Opportunities
- The PREDATOR platform could expand into new cancer treatments beyond current applications.
- WTX-124 and WTX-330 have potential for combination therapies with immune checkpoint inhibitors.
- Growth in the biotechnology sector offers opportunities for increased funding and partnerships.
Threats
- Competition in the biopharmaceutical sector may impact market share for cancer therapies.
- Regulatory challenges could delay clinical trials for WTX-124 and WTX-330.
- The high costs of developing new cancer treatments may strain financial resources.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.